Tab Application Banner
  • Users Online: 109
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 9  |  Issue : 4  |  Page : 178-183

Association of HLA-E*01:01/*01:03 polymorphism with methotrexate-based treatment response in South Indian rheumatoid arthritis patients


1 Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605 006, India; INSERM, UMRS 1160, Saint Louis Hospital, Paris F75010, France
2 Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605 006, India
3 INSERM, UMRS 1160, Saint Louis Hospital, Paris F75010, France
4 Jean Dausset Laboratory of Immunology and Immunogenetics and LabEx Transplantex, Saint Louis Hospital, Paris
5 INSERM, UMRS 1160, Saint Louis Hospital, Paris F75010, France; Jean Dausset Laboratory of Immunology and Immunogenetics and LabEx Transplantex, Saint Louis Hospital, Paris F75010, France

Correspondence Address:
Vir Singh Negi
Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry 605 006, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.injr.2014.08.002

Rights and Permissions

Objectives: Non-classical HLA-E molecules may influence the disease susceptibility and phenotype including treatment response in chronic inflammatory disorders such as Rheumatoid Arthritis (RA) by virtue of their capacity to modulate innate immune pro- cesses. This study was carried out to investigate the role of HLA-E polymorphism in RA susceptibility, clinical and serological phenotype as well as treatment response. Methods: Genomic DNA from 221 RA patients and 200 healthy controls (HC) were typed for HLA-E rs2844724 (C/T) and rs1264457 (HLA-E*01:01/*01:03) single nucleotide polymorphisms (SNPs) using the TaqMan 5'nuclease assay consisting of allele-specific fluorogenic oligo- nucleotide probes. Results: Our study did not find any association between HLA-E polymorphism and RA susceptibility or disease phenotype. However, it was observed that the frequency of HLA- E*01:03 allele was higher in all RA cases (Pc ¼ 0.03,OR ¼ 3.02, 95% CI ¼ 1.06e9.39), young onset RA (YORA) (Pc ¼ 0.03, OR ¼ 3.20, 95% CI ¼ 1.11e9.98) and female RA (Pc ¼ 0.04, OR ¼ 3.04, 95% CI ¼ 1.06e9.46) patients who responded well (good responders) to a com- bination of non-biological disease modifying anti rheumatic drugs (DMARDs), metho- trexate (MTX) and hydroxychloroquine (HCQ) as compared to non-responders. Moreover, the frequency of rs2844724 T allele and TT genotype was observed to be higher in patients with low titers of rheumatoid factor (RF) than those with high titers (90% vs. 77% and 79% vs. 59% respectively), although the difference did not reach statistical significance. Conclusion: The results of our study suggest that HLA-E rs1264457 may influence the patient response to treatment with methotrexate-based DMARD therapy. Thus, it may be a useful genetic marker for treatment response in patients with RA.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed455    
    Printed12    
    Emailed0    
    PDF Downloaded90    
    Comments [Add]    
    Cited by others 1    

Recommend this journal